MYGN (Myriad Genetics, Inc.) Stock Financials & Earnings

MYGNMyriad Genetics, Inc.

Mkt Cap$487M

Healthcare·Medical - Diagnostics & Research·🇺🇸 United States·NASDAQ

Revenue (TTM)$825M

Net Income (TTM)-$366M

EPS (TTM)-$3.94

Free Cash Flow (TTM)-$16M

Gross Margin69.9%

Op. Margin-31.7%

Net Margin-44.4%

FCF Margin-2.0%

P/S Ratio (TTM)0.6x

P/E Ratio (TTM)—

YoY Rev Growth-1.6%

Employees—

Earnings Reports

▶Q4 2025

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tes...

CEO Samraat S. RahaIPO Oct 6, 1995myriad.com

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$181M	$122M	-$52M
Q2 23	$184M	$126M	-$114M
Q3 23	$192M	$134M	-$60M
Q4 23	$197M	$135M	-$31M
Q1 24	$202M	$138M	-$28M
Q2 24	$212M	$147M	-$37M
Q3 24	$213M	$150M	-$20M
Q4 24	$211M	$151M	-$39M
Q1 25	$196M	$134M	-$29M
Q2 25	$213M	$152M	-$329M
Q3 25	$206M	$144M	-$23M
Q4 25	$210M	$147M	$120M

Valuation

Quarter	P/S	P/E
Q1 23	2.8x	—
Q2 23	2.7x	—
Q3 23	1.8x	—
Q4 23	2.2x	—
Q1 24	2.5x	—
Q2 24	2.7x	—
Q3 24	3.0x	—
Q4 24	1.5x	—
Q1 25	1.0x	—
Q2 25	0.6x	—
Q3 25	0.8x	—
Q4 25	0.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$33M	-$57M
Q2 23	-$900K	-$20M
Q3 23	-$22M	-$40M
Q4 23	-$55M	-$68M
Q1 24	-$19M	-$27M
Q2 24	$3M	-$6M
Q3 24	$700K	-$6M
Q4 24	$7M	$700K
Q1 25	-$16M	-$25M
Q2 25	-$14M	-$21M
Q3 25	$21M	$18M
Q4 25	$11M	$11M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$24M
Q2 23	$19M
Q3 23	$18M
Q4 23	$14M
Q1 24	$9M
Q2 24	$9M
Q3 24	$6M
Q4 24	$6M
Q1 25	$8M
Q2 25	$7M
Q3 25	$3M
Q4 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+9.9%	+29.8%
Q2 23	+2.3%	+50.8%
Q3 23	+22.7%	+25.1%
Q4 23	+10.6%	+1.9%
Q1 24	+11.6%	-1.4%
Q2 24	+15.3%	-16.6%
Q3 24	+11.2%	-7.4%
Q4 24	+7.1%	+9.5%
Q1 25	-3.1%	-2.3%
Q2 25	+0.8%	+118.7%
Q3 25	-3.6%	-1.8%
Q4 25	-0.4%	-64.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$8M	4.1%
Q2 23	$11M	6.1%
Q3 23	$12M	6.0%
Q4 23	$10M	5.3%
Q1 24	$12M	5.9%
Q2 24	$15M	6.9%
Q3 24	$12M	5.8%
Q4 24	$11M	5.2%
Q1 25	$10M	4.8%
Q2 25	$11M	5.0%
Q3 25	$12M	5.9%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 23	$23M	$152M	—
Q2 23	$21M	$218M	—
Q3 23	$24M	$136M	—
Q4 23	$21M	$33M	—
Q1 24	$25M	$71M	$69M
Q2 24	$27M	$72M	$73M
Q3 24	$29M	$139M	—
Q4 24	$32M	—	$284M
Q1 25	$28M	$67M	$69M
Q2 25	$26M	$67M	$72M
Q3 25	$28M	$68M	$71M
Q4 25	$26M	$56M	$69M

Revenue Segments

Quarter

Revenue by Geography

Quarter	Non-US	United States
Q3 23	$20M	$172M
Q1 24	$19M	$183M
Q2 24	$17M	$195M
Q3 24	$17M	$196M
Q4 24	$15M	$196M
Q1 25	$14M	$182M
Q2 25	$15M	$198M
Q3 25	$14M	$192M
Q4 25	$13M	$197M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$54M	$25M	$79M
Q2 23	$103M	$19M	$122M
Q3 23	$76M	$10M	$86M
Q4 23	$132M	$9M	$141M
Q1 24	$97M	$7M	$104M
Q2 24	$92M	$5M	$97M
Q3 24	$100M	$0	$100M
Q4 24	$102M	$0	$102M
Q1 25	$92M	$0	$92M
Q2 25	$74M	$0	$74M
Q3 25	$145M	$0	$145M
Q4 25	$150M	$0	$150M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	81M	-0.2%
Q2 23	82M	+0.5%
Q3 23	82M	+0.2%
Q4 23	86M	+5.1%
Q1 24	90M	+4.4%
Q2 24	91M	+0.8%
Q3 24	91M	+0.3%
Q4 24	91M	+0.2%
Q1 25	91M	+0.3%
Q2 25	93M	+1.2%
Q3 25	93M	+0.6%
Q4 25	93M	+0.2%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$355K	2K
FY 15	$342K	2K
FY 16	$321K	2K
FY 17	$322K	2K
FY 18	$327K	3K
FY 19	$237K	3K
FY 20	$206K	3K
FY 21	$288K	2K
FY 22	$261K	3K
FY 23	$279K	3K
FY 24	$310K	3K
FY 25	$305K	3K